A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Location:

Baltimore

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00092078

Coordinator:

Ilene Wiggins, RN (Baltimore)

Anna Wimpelberg (Washington)

Enrollment:

Closed

Trial Period:

Ongoing

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1 coinfected participants who received direct-acting antiviral (DAA) therapy for HCV infection.

Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV monoinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV/HIV-1 coinfected participants who achieved a SVR at least 12 weeks after treatment completion; or HCV monoinfected participants who achieved a SVR as at least 12 weeks after treatment completion.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More